IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...
As part of this shift in focus, Schwarzer stepped down as CEO, with Mary Beth Harler appointed as his replacement. Harler joined IGM in 2021 as president of autoimmunity and inflammation following an ...
The new study included 82 patients whose large B-cell lymphoma had failed to respond to treatment or had returned after a ...